Motor Neuron Disease

1. Barohn RJ, Wolfe GI, Saperstein DS, Dimachkie MM, Katz JS. Pattern recognition of neuropathy and neuronopathy. RRNMF Neuromuscul J. 2024;5(1):44–74.

2. Barohn RJ, Wolfe GI, Saperstein DS, Dimachkie MM. Pattern recognition approach to neuropathy and neuronopathy. Neurol Clin. 2025;43(4):617–635.

3. Berdyński M, Miszta P, Safranow K, Andersen PM, Morita M, Filipek S, Żekanowski C, Kuźma-Kozakiewicz M. SOD1 mutations associated with amyotrophic lateral sclerosis: analysis of variant severity. Sci Rep. 2022;12:103.

4. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619–1620.

5. Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):807–830.

6. BrainStorm Cell Therapeutics Inc. BrainStorm announces new survival data from expanded access program cohort: 90% of ALS patients survived over 5 years with NurOwn®. Press release. 2025.

7. Cudkowicz ME, Lindborg SR, Goyal NA, Miller RG, Burford MJ, Berry JD, et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 2022;65(3):291–302.

8. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–256.

9. Dimachkie MM, Barohn RJ, Katz JS. Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants. Neurol Clin. 2013;31(2):533–555.

10. Ferrer. Ferrer reports top-line results from phase III ADORE study in ALS. Press release. 2024.

11. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017–3026.

12. Goutman SA, Hardiman O, Al-Chalabi A, Chio A, Savelieff MG, Kiernan MC, Feldman EL. Amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):480–493.

13. Gregory J, Fagegaltier D, Phatnani HP, Harms MB. Genetics of amyotrophic lateral sclerosis. Curr Genet Med Rep. 2020;8:121–131.

14. Grunseich C, Fischbeck KH. Spinal and bulbar muscular atrophy. Neurol Clin. 2015;33(4):847–854.

15. Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ. Symptom management and end-of-life care in amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):889–908.

16. Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM. Amyotrophic lateral sclerosis regional variants. Neurol Clin. 2015;33(4):775–785.

17. Johnson A. Here’s why ALS drug Relyvrio is being removed from the market—and what that means for patients. Forbes. 2024.

18. Katz JS, Wolfe GI, Andersson PB, Saperstein DS, Elliott JL, Nations SP, et al. Lower motor neuron syndromes: clinical features and diagnosis. Neurology. 1999;53(5):1071–1076.

19. Katz JS, Wolfe GI, Bryan WW, Jackson CE, Amato AA, Barohn RJ. Electrophysiologic findings in multifocal motor neuropathy. Neurology. 1997;48:700–707.

20. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831–846.

21. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(9013):1425–1431.

22. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77–79.

23. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–165.

24. Lewis-Kraus G. When dying patients want unproven drugs. New Yorker. 2023.

25. Liewluck T, Saperstein DS. Progressive muscular atrophy. Neurol Clin. 2015;33(4):761–773.

26. Lindborg SR, Goyal NA, Katz JS, et al. Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes. Muscle Nerve. 2024;69:719–729.

27. Maia M. Edaravone formulation FAB122 fails to slow ALS progression. ALS News Today. 2024.

28. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(19):1713–1722.

29. Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109–119.

30. Miller TM, Cudkowicz ME, Shaw PJ, et al. Long-term tofersen in SOD1 amyotrophic lateral sclerosis. JAMA Neurol. 2025; Epub ahead of print.

31. Paganoni S, Macklin EA, Hendrix S, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate–taurursodiol in amyotrophic lateral sclerosis. N Engl J Med. 2021;384:915–923.

32. Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–930.

33. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial ALS. Nature. 1993;362(6415):59–62.

34. Saperstein DS, Amato AA, Wolfe GI, Katz JS, Nations SP, Jackson CE, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis–Sumner syndrome. Muscle Nerve. 1999;22(5):560–566.

35. Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM. Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):735–748.

36. Stino A, Dimachkie MM, Katz JS. Immune-mediated neuropathies other than typical CIDP. Neurol Clin. 2025;43:781–797.

37. Woolley SC, Strong MJ. Frontotemporal dysfunction and dementia in amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):787–805.

38. Writing Group on Behalf of the Edaravone ALS 19 Study Group. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis. Lancet Neurol. 2017;16(7):505–512.